Third Quarter 2024 and Recent Operating Highlights CNM-Au8 for the treatment of ALS On November 1, 2024, the Company met with the FDA in a Type C meeting to discuss the potential for an accelerated ...
U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 2024 was $4.1 million, an increase of 14% compared to $3.6 million in the third quarter of 2023. For the three ...
Samsung offered an early preview of its upcoming One UI 7 operating system at its annual developer conference, showcasing significant enhancements. The next iteration of the system will be compatible ...